Fluidigm Announces Collaboration Agreement with the Abu Dhabi Stem Cells Center to Accelerate Imaging Mass Cytometry in Development of Targeted Stem Cell Therapies
Excerpt from the Press Release:
Collaboration Enables Further Expansion of Mass Cytometry in the Middle East
SOUTH SAN FRANCISCO, Calif., Feb. 17, 2022 (GLOBE NEWSWIRE) — Fluidigm Corporation (Nasdaq: FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, today announced a collaboration agreement with the Abu Dhabi Stem Cells Center (ADSCC) for development of targeted stem cell therapies and research applications utilizing two Fluidigm® mass cytometry and tissue imaging technologies: Imaging Mass Cytometry™ (IMC™) and the Maxpar® Direct™ Immune Profiling Assay™.
The ADSCC, founded in 2019, is a specialist health care center that focuses on cell therapy and regenerative medicine in addition to cutting-edge stem cell research. The Center collects, processes, characterizes, and stores cell products for clinical application in both regenerative medicine and hematopoietic transplantation.
The ADSCC collaboration with Fluidigm represents an opportunity to increase the visibility of mass cytometry technology for potential new customers in the Middle East and to establish a foundation for expansion in the region.
“We seek out the technologies that can most effectively provide meaningful insights as we work to develop new approaches to stem cell therapies, and Fluidigm’s IMC and immune profiling tools are exceptional in this regard,” said Dr. Yendry Ventura Carmenate, Specialist in Immunology, General Manager of ADSCC. “We believe these tools will ultimately accelerate our global expertise in this progressive area of medicine and inform targeted therapies for our patients.”
Click the button below to read the entire Press Release:
Discover What Sets TrialStat Apart From Ordinary Data Management
Click the image or button below to explore our interactive infographic which illustrates the comprehensive and unique capabilities of the TrialStat eClinical Suite.
Request Your Demo Today!
From rapid database build through database lock, we deliver consistent quality on-time and on-budget. Ready to upgrade your eClinical toolkit?